Stock AnalizKodiak Sciences Inc. KOD
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Kodiak Sciences Inc. (KOD) is a healthcare company listed in the US with a market value of about $7.3B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -59%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$230M | -$176M | -$260M | -$334M | -$267M | -$133M | -$47M | -$41M | -$28M | -$17M |
| Free cash flow | -$137M | -$118M | -$196M | -$243M | -$199M | -$87M | -$40M | -$29M | -$18M | -$17M |
| EPS (diluted) | $-4.32 | $-3.35 | $-4.97 | $-6.39 | $-5.16 | $-2.91 | $-1.25 | $-2.77 | $-3.72 | $-2.38 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -85.5% | -66.9% | -63.1% | -51.5% | -28.4% | -11.5% | -11.2% | -24.0% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $129.50, 16% above the current price; targets range from $103.00 to $150.00; the consensus rating is “Strong buy”; expected EPS is $-4.03 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Kodiak Sciences pay a dividend?
Not currently.
Is Kodiak Sciences a good stock to buy?
We do not give buy or sell advice. Kodiak Sciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.